The 2011 Molecular Diagnostics Market: DNA Probes and Biochips

Oct. 21, 2011 - PRLog -- Venture Planning Group (www.VPGMarketResearch.com), an international publishing and management consulting firm, is pleased to announce the completion of a new 1,050-page report, “The 2011 Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers"
(http://www.vpgmarketresearch.com/molecular-diagnostics). The report is designed to help current suppliers and potential market entrants identify and evaluate major opportunities emerging in the global molecular diagnostics market during this decade.

This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during this decade. The report explores business and technological trends in the US, five major European countries, (France, Germany, Italy, Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.

The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new DNA probe and biochip technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next ten years.

Contains 1,050 pages and 96 tables

To review or order this report, visit http://www.vpgmarketresearch.com/2011-molecular-diagnosti...

Contact

Robert Fisher
Healthcare Research
robert@vpgcorp.com
+1 212 564 2838
http://www.VPGMarketResearch.com

# # #

Venture Planning Group is an international market research, publishing and management consulting firm, providing syndicated and custom services to corporate executives and key decision-makers in the Diagnostics, Pharmaceutical, Imaging, Orthopedics, Biotechnology, Chemical, Flavors & Fragrances, Food & Beverage, Electronics, and other industries.

During numerous proprietary single-client consulting assignments and over 500 multiclient studies, VPG has developed an extensive database on various industries, technologies, markets, companies, products, and executives worldwide.

VPG has served over 1,000 corporations in 70 countries, and has established a broad network of worldwide contacts with industry executives, opinion leaders, and experts from leading universities, research centers, the financial community and the government.

Specialties
Market Intelligence Surveys, Opportunity Analyses, New Technology/Product Assessments, Acquisition/Joint Venture Evaluations.